All In Biotech

Drug Trial Radar · NCT05351801

Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Jun 21, 2023

Primary completion

Sep 29, 2028

Study completion May 31, 2029

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
Apr 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chronic neuropathic pain (CNP) is disabling. Research on frontline treatments for CNP, shows inconsistent outcomes and dissatisfaction among Veterans. Veterans and clinicians have shown significant interest in cannabis derivatives (THC, CBD) for neuropathic pain control, but there are no well-controlled trials guiding expectations for benefit and adverse outcomes associated with cannabis for CNP. Because Veterans are likely to present with pain and pain-related polymorbidity significantly differing from that of civilians, a well-structured clinical trial of cannabinoids for Veterans with CNP is vital.

Conditions

  • Neuropathic Pain
  • Peripheral Neuropathic Pain

Interventions

  • THC (Syndros)Drug

    Participants will receive a target dose of 10mg per day of THC (Syndros).

  • CBD (Epidolex)Drug

    Participants will receive a target dose of 800 mg per day of CBD (Epidolex).

  • THC + CBD (Nabiximols)Drug

    Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the short-term efficacy of THC, CBD, or THC+CBD vs Placebo on Neuropathic Pain as measured by the Numeric Rating Scale of PainTime frame: Baseline, Week 6

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • VA San Diego Healthcare System, San Diego, CA

    San Diego, California · Recruiting

  • VA Greater Los Angeles Healthcare System, West Los Angeles, CA

    West Los Angeles, California · Active not recruiting

  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT

    West Haven, Connecticut · Recruiting

  • Providence VA Medical Center, Providence, RI

    Providence, Rhode Island · Recruiting

  • South Texas Health Care System, San Antonio, TX

    San Antonio, Texas · Recruiting

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA

    Seattle, Washington · Terminated

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.